Phastar
Phastar is a London-based specialist biometrics and data science CRO serving pharmaceutical, biotech, and health agency clients with statistical consulting, clinical data management, data visualization, and strategic consulting services for regulated clinical trials.
- Company typePrivate
- Founded2007
- HeadquartersLondon, United Kingdom
- Headcount251–500
- GTM typeB2B
- OfferingServices
What Phastar does
Phastar is a global specialist biometrics and data science contract research organization (CRO) founded in 2007 and headquartered in London. The company serves pharmaceutical, biotechnology, and health agency clients by providing statistical consulting, clinical trial reporting, data science, and data management services for regulated clinical development programs. Phastar targets sponsors seeking Functional Service Provider (FSP) engagement models with deep biometrics domain expertise rather than full-service bundled offerings.
The company's core service portfolio comprises four integrated offerings: Biometrics Services (statistical analysis, clinical trial design, and statistical programming), Data Science Services (advanced analytics for clinical development), Clinical Data Management (handling, validation, and regulatory compliance), and Data Visualization Solutions (acquired via Danish firm S-Cubed ApS in January 2023, adding specialized visual analytics for regulated environments). A Strategic Consulting practice, launched in June 2025 under Billy Amzal, extends the offering into advisory services for adaptive trial designs, Bayesian statistics, real-world evidence integration, and innovative methodologies including patient simulators and synthetic patients.
Phastar operates a project-based and FSP professional services revenue model with quote-based, non-publicly-disclosed pricing typical of the CRO industry. The company has grown to approximately 550 employees globally following the S-Cubed acquisition, and is privately held under the sponsorship of Charterhouse Capital Partners (invested January 2021). Distribution is direct enterprise sales targeting pharma/biotech sponsors and health agencies, with senior leadership engagement as the primary commercial motion. The Clinical Trial Data Visualization sub-market in which Phastar competes is projected to grow from $0.89 billion in 2025 to $1.82 billion by 2030 at approximately 15% CAGR, providing a supportive demand backdrop.
Phastar firmographics
Firmographics- Name
- Phastar
- Website
- https://phastar.com
- Company type
- Private
- Founded year
- 2007
- Operating status
- Operating
- Headcount range
- 251–500 employees
- Short description
- Phastar is a London-based specialist biometrics and data science CRO serving pharmaceutical, biotech, and health agency clients with statistical consulting, clinical data management, data visualization, and strategic consulting services for regulated clinical trials.
- Ownership category
- akta.pro rank
Phastar industry classification
Industry- Product category
- Clinical Research Organization (CRO) Services
- NAICS
- Research and Development in the Physical, Engineering, and Life Sciences (54171), Scientific Research and Development Services (5417)
- SIC
- Services-Commercial Physical & Biological Research (8731)
- akta.pro primary industry
- Clinical Data Management, Biostatistics & Statistical Programming CROs (HLAGAAAF)
- akta.pro secondary industries
- Clinical CROs (Phase I–IV) (HLAGAAAA), Real-World Evidence (RWE), HEOR & Epidemiology CROs (HLAGAAAK)
Keywords
Where Phastar is headquartered
LocationHeadquarters
- HQ city
- London
- HQ country
- United Kingdom
- HQ region
- Europe
Offices1 record
Markets served
Phastar business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Operations, Technology or R&D, Marketing or Sales, Infrastructure
Revenue model
- Contract Research Organization Services: Phastar provides specialized biometrics and data science services as a CRO, likely operating on project-based or functional service provider (FSP) models typical in the clinical research industry
Go-to-market motion2 records
Distribution channels1 record
Marketing channels2 records
Phastar product offering
Product offeringCore offering
Phastar is a specialist contract research organization (CRO) providing biometrics and data science services to pharmaceutical and biotech sponsors. Its core offerings include biometrics services (statistical analysis, trial design, statistical programming), data science services, and clinical data management, supplemented by data visualization capabilities acquired through S-Cubed ApS and strategic consulting on adaptive trial designs and real-world evidence.
Product overview
Phastar is a global specialist biometrics and data science contract research organization (CRO) offering a unified platform of services for pharmaceutical and biotech clients. The core offering consists of Biometrics Services, Data Science Services, and Clinical Data Management, which work together to support the full clinical development lifecycle. The portfolio was expanded through the January 2023 acquisition of S-Cubed ApS, adding Data Visualization Solutions to enhance data presentation capabilities in regulated environments. Strategic Consulting services, led by Head of Strategic Consulting Billy Amzal, provide advisory capabilities on adaptive trial designs and real-world evidence integration. The combined expertise aims to improve data analysis and visualization across clinical trial programs.
Differentiator
Problem solved
Functional benefit
Products and services
- Biometrics Services
- Data Science Services
- Clinical Data Management
- Data Visualization Solutions
- Strategic Consulting
Quantifiable outcome
- Workforce expanded to approximately 550 people globally
- +1 more outcomes
Companies that use Phastar
Customer profileSegments2 records
Ideal customer profiles2 records
Phastar technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability2 records
Feature2 records
Phastar partnerships and signals
Strategic signalPartnerships
Two partnerships are on record, tiered minor and core.
- Quinten HealthminorBilly Amzal, previously CEO of Quinten Health, joined Phastar as Head of Strategic Consulting. Phastar will continue collaborating with Quinten Health on strategic initiatives, leveraging their existing relationship in health analytics and consulting.
- S-Cubed ApScoreAcquired Danish data visualization company S-Cubed ApS in January 2023 to strengthen Phastar's presence in the Nordic region and enhance its data visualization capabilities for clinical data management in regulated environments.
Scale indicators4 records
Recent moves6 records
Expansion highlights6 records
Phastar competitors and assessment
Company assessmentDirect peers
- Veramed: Veramed is a UK-based specialist biometrics CRO offering biostatistics, statistical programming, and data management. Its boutique scale, biometrics focus, and pharma/biotech sponsor base closely mirror Phastar's positioning.
- Statistics Collaborative: Statistics Collaborative is a boutique biometrics CRO specializing in biostatistics, statistical programming, and clinical study reporting. Its specialist focus and pharma/biotech sponsor mix make it a relevant small-scale peer to Phastar.
- Cytel: Cytel is the leading specialist biometrics and statistical CRO, providing biostatistics, statistical programming, and clinical data management services to pharma and biotech sponsors. It is the closest direct competitor to Phastar's biometrics FSP offering.
- Rho: Rho is a mid-sized specialty CRO with strong biostatistics and clinical data management capabilities serving biotech and pharma sponsors. It competes with Phastar for FSP biometrics engagements in the mid-market sponsor segment.
Broad incumbents
- Parexel: Parexel is a major full-service CRO with deep biometrics and biostatistics capabilities following the 2021 PAI integration. It competes with Phastar for FSP and full-service engagements, particularly among biotech sponsors.
- Clario: Clario (formed from ERT and Bioclinica) provides clinical trial technology and services including eCOA, imaging, and data management. Its data visualization and clinical data tooling overlap with Phastar's post-S-Cubed capabilities.
- ICON plc: ICON is a top-three global CRO with extensive biometrics, data management, and FSP capabilities. Its broad portfolio overlaps with Phastar across pharma/biotech biometrics services and represents a competitive threat for mid-tier sponsor accounts.
- Medidata (Dassault Systèmes): Medidata offers the Rave clinical data platform and end-to-end clinical trial technology used by sponsors and CROs. Its Rave data management and analytics capabilities compete with and complement Phastar's biometrics services.
- IQVIA: IQVIA is the largest global CRO with full-service clinical operations and a large biometrics/Real World Solutions practice. It competes with Phastar for enterprise FSP contracts and serves as the dominant reference point for CRO multiples.
Regional players
- Worldwide Clinical Trials: Worldwide Clinical Trials is a mid-sized CRO with strong biostatistics and clinical pharmacology capabilities primarily serving biotech sponsors in North America and Europe. It is comparable to Phastar in scale and sponsor focus, though with less UK/European concentration.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat3 records
Key risks6 records
Key highlights6 records
Customer concentration
Phastar social profiles
Digital presencePhastar financial estimates
Financial estimateRevenue estimate
Valuation estimate
Phastar leadership team
Management profileNumber of profiles
Profiles1 record
Phastar subsidiaries and ownership
Company hierarchySubsidiaries1 record
Phastar funding detail
Funding detailFunding overview
Funding rounds1 record
Investors1 record
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Phastar M&A and investment
M&A and investmentM&A2 records
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Phastar
What does Phastar do?
Phastar is a specialist contract research organization (CRO) providing biometrics and data science services to pharmaceutical and biotech sponsors. Its core offerings include biometrics services (statistical analysis, trial design, statistical programming), data science services, and clinical data management, supplemented by data visualization capabilities acquired through S-Cubed ApS and strategic consulting on adaptive trial designs and real-world evidence.
Is Phastar a public or private company?
Phastar is a private company. It is classified as private equity controlled and is currently operating.
When was Phastar founded?
Phastar was founded in 2007. It employs 251 to 500 people.
Where is Phastar based?
Phastar is headquartered in London, United Kingdom, in the Europe region.
How does Phastar make money?
One revenue line is on record: contract Research Organization Services.
Who are Phastar's main competitors?
Direct peers on record are Veramed, Statistics Collaborative, Cytel and Rho. Broad incumbents are Parexel, Clario, ICON plc, Medidata (Dassault Systèmes) and IQVIA. Worldwide Clinical Trials is listed as a regional player.
Does Phastar have an API?
No public API is recorded for Phastar.
What industry is Phastar in?
Phastar's product category is Clinical Research Organization (CRO) Services. Its primary akta.pro industry code is HLAGAAAF, Clinical Data Management, Biostatistics & Statistical Programming CROs, with a secondary code of HLAGAAAA, Clinical CROs (Phase I–IV). Its NAICS code is 54171 and its SIC code is 8731.